Patents Assigned to AlonBio Ltd.
  • SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH
    Publication number: 20240002347
    Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 4, 2024
    Applicant: AlonBio Ltd.
    Inventors: Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
  • Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
    Patent number: 11780814
    Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: October 10, 2023
    Assignee: AlonBio Ltd.
    Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
  • Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
    Patent number: 11261159
    Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: March 1, 2022
    Assignee: AlonBio Ltd.
    Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg